H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $40
Anavex Life Sciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $40 Price Target
Anavex Life Sciences: Buy Rating Driven by Promising Blarcamesine Developments and Market Expansion
JonesTrading Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $15
Anavex Life Sciences Is Maintained at Buy by EF Hutton
Anavex Life Sciences Analyst Ratings
H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $40
Buy Rating on Anavex Life Sciences Amid Anticipated European Approval and Market Opportunity for Alzheimer's Drug Blarcamesine
JonesTrading Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $15
Buy Rating on Anavex Life Sciences: Upcoming Catalysts and Positive Trial Outcomes Fuel Optimism
HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $40 Price Target
Anavex Life Sciences Analyst Ratings
H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $40
Buy Rating Affirmed for Anavex Life Sciences on Blarcamesine's Promising Alzheimer's Treatment Potential
JonesTrading Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $15
Buy Rating Affirmed: Anavex Life Sciences' Promising Alzheimer's Drug Shows Potential for Approval
Anavex Life Sciences Analyst Ratings
JonesTrading Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $15
Anavex Life Sciences Price Target Announced at $46.00/Share by EF Hutton